1-(pyridin-3-ylmethyl)thiourea | 73161-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(pyridin-3-ylmethyl)thiourea
• 英文别名: pyridin-3-ylmethyl-thiourea；N-(pyridin-3-ylmethyl)thiourea；N-(3-pyridinylmethyl)thiourea；pyridin-3-ylmethylthiourea
• CAS: 73161-70-3
• 化学式: C₇H₉N₃S
• 分子量: 167.235
• InChiKey: IDUGONKKOKQBPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(pyridin-3-ylmethyl)thiourea 生成 5,5-dimethyl-2-(pyridin-3-ylmethylamino)-4,6-dihydro-1,3-benzothiazol-7-one;hydrobromide
  参考文献：
  名称：

  LIN Y.; SEIFERT C. M.; KANG S. M.; DUSZA J. P.; LANG S. A. JR., J. HETEROCYCL. CHEM., 1979, 16, NO 7, 1377-1383

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨甲基吡啶 、 1-[(4-fluorophenyl)methyl]-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]-1H-benzimidazol-2-amine 在 silica gel 、 氯仿 、 甲醇 、 丙酮 、 异丙醚 、 N-[2-[4-[[1-(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-ethyl 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以yielding 3.4 parts (65.7%) of N-[2-[4-[[1-(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-ethyl]-N'-(3-pyridinylmethyl)thiourea的产率得到1-(pyridin-3-ylmethyl)thiourea
  参考文献：
  名称：

  Novel N-(bicyclic heterocyclyl)-4-piperidinamines

  摘要：

  这句话的中文翻译为：具有抗组胺和血清素拮抗作用的新型N-(双环杂环基)-4-哌啶胺类化合物，可用于治疗过敏性疾病。

  公开号：

  US04820822A1

文献信息

• Synthesis and structure–activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors
  作者：Xiaohu Ouyang、Xiaoling Chen、Evgueni L. Piatnitski、Alexander S. Kiselyov、Hai-Ying He、Yunyu Mao、Vatee Pattaropong、Yang Yu、Ki H. Kim、John Kincaid、Leon Smith、Wai C. Wong、Sui Ping Lee、Daniel L. Milligan、Asra Malikzay、James Fleming、Jason Gerlak、Dhanvanthri Deevi、Jacqueline F. Doody、Hui-Hsien Chiang、Sheetal N. Patel、Ying Wang、Robin L. Rolser、Paul Kussie、Marc Labelle、M. Carolina Tuma

  DOI：10.1016/j.bmcl.2005.08.056

  日期：2005.12

  triazole-containing chemical series was shown to inhibit tubulin polymerization and cause cell cycle arrest in A431 cancer cells with EC(50) values in the single digit nanomolar range. Binding experiments demonstrated that representative active compounds of this class compete with colchicine for its binding site on tubulin. The syntheses and structure-activity relationship studies for the triazole derivatives

  一种新型的含有三唑的化学系列显示抑制微管蛋白聚合并导致细胞周期停滞在EC（50）值在一位数纳摩尔范围内的A431癌细胞。结合实验表明，这类代表性的活性化合物与秋水仙碱竞争其在微管蛋白上的结合位点。本文描述了三唑衍生物的合成和结构-活性关系研究。
• The synthesis of substituted 2-aminothiazoles
  作者：Yang-i Lin、C. M. Seifert、S. M. Kang、J. P. Dusza、S. A. Lang

  DOI：10.1002/jhet.5570160718

  日期：1979.11

  The preparation of 4- and 5-acyl- and aroyl-2-substituted aminothiazoles is described. The condensation of thioureas with acyl halides leading to 4,5-disubstituted-2-aminothiazoles and 7-(4H)benzothiazolones is discussed. A discussion of the isolation of various intermediates and the mechanistic pathway is also included. A number of 2-anilino or 2-benzyl-4- or 5-aroylthiazoles possessed moderate oral

  描述了4-和5-酰基-和芳酰基-2-取代的氨基噻唑的制备。讨论了硫脲与酰基卤的缩合生成4,5-二取代-2-氨基噻唑和7-（4 H）苯并噻唑酮。还包括各种中间体的分离和机理途径的讨论。许多2-苯胺基或2-苄基-4-或5-芳酰基噻唑具有中等的口服抗结核活性（2）。
• SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS
  申请人：Polisetti Dharma Rao

  公开号：US20120029029A1

  公开（公告）日：2012-02-02

  The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.

  本发明涉及取代噻唑-2-基胺衍生物及其药学上可接受的盐，其抑制11βHSD1并可能有助于治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的疾病。本发明还涉及包含这些化合物的制药组合物以及在治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的疾病、疾病或病况中使用这些化合物和组合物的用途。
• Thiazole Derivatives and Use Thereof
  申请人：Quattropani Anna

  公开号：US20090029998A1

  公开（公告）日：2009-01-29

  The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

  本发明涉及公式（I）的噻唑衍生物，特别是用于治疗和/或预防自身免疫性疾病和/或炎症性疾病，心血管疾病，神经退行性疾病，细菌或病毒感染，肾脏疾病，血小板聚集，癌症，移植，移植排斥或肺损伤。
• Novel quinazoline derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20070010671A1

  公开（公告）日：2007-01-11

  The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(1)，并作为MCH受体拮抗剂。这些化合物在制药组合物中的使用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴食障碍（包括贪食症、厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆）、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。